Accendra Health, Inc. is in the midst of a multiyear turnaround focusing on at-home medicine after selling its hospital supply unit and improving its balance sheet. The company recently refinanced its debt, reducing gross debt by about $100 million and extending maturities, which improves liquidity and the chances of successful long-term deleveraging. Management confirmed full-year guidance, but ongoing margin pressures and slow volume growth mean EBITDA is expected to be at the lower end of the forecast. Despite these challenges, the improved capital structure supports a Buy rating with a price target of around $7 by 2030, though the investment remains speculative due to high leverage.
Allianz reported a record operating profit of €4.87 billion in Q2 2026, a 10.6% increase year-over-year, driven by strong asset management and life and health segments. Despite this, shareholders' core net income declined by 8.7% to €2.60 billion, mi...
Quantum Corporation is set to report earnings on August 10, 2026, with analysts expecting a loss of $0.15 per share and revenue of $75.05 million. The company shows signs of financial strain, including a negative price-to-earnings ratio of -1.45 and ...
Take-Two Interactive's stock rose following a strong first-quarter earnings report that beat revenue and EBITDA estimates, driven by robust operational results. Analyst Roth Capital reaffirmed a "Buy" rating and raised the price target to $300, refle...
Airbnb's stock surged to a 52-week high of $176.40 following strong financial results, including a 17% revenue increase and 16% growth in Gross Booking Value. Analysts from Evercore ISI and Wedbush raised their price targets to $190 and $200 respecti...
Rapid Micro Biosystems reported Q2 2026 revenue of $8.05 million, an 11% increase year-over-year, driven by strong product and consumable sales. The company placed its 200th Growth Direct system, boosting recurring revenue to 63% of total revenue. Ho...
